Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Training Management

Training Management

View Detailed Analysis

Analytics Overview

101
Form 483s Issued
13
483s converted to WL
153
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
19 Nov 2024
Dr. Reddy's Laboratories Limited (Unit II)
Drugs
27 Sep 2024
Biocon Sdn Bhd
Drugs
20 Sep 2024
Aarti Drugs Limited
Drugs
29 Aug 2024
Zydus Lifesciences Limited
Drugs
28 Aug 2024
Empower Pharmacy
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Justin A Boyd
11
1
Sena G Dissmeyer
10
0
Pratik S Upadhyay
10
0
Saleem A Akhtar
8
0
Arsen Karapetyan
7
0
TITLE/ COMPANY Issue Date Status Details
Appropriate controls are not exercised over computers or related systems to assure...
Dr. Reddy's Laboratories Limited (Unit II)
19 Nov 2024 Normal Justification: Employees' inability to perform basic operations indicates insufficient training and knowledge transfer on software use.
Excerpt: You have not trained your personnel on their operations (i.e. Empower 3.6.1...)
View Details
Your firm failed to establish adequate written procedures for production and process controls
Biocon Sdn Bhd
27 Sep 2024 Normal Justification: Observation highlights the gap in operator training specifically related to SOP training for end filling operations.
Excerpt: Operators are neither trained nor provided instructions in the SOP for filling machine operations.
View Details
Responsibilities and procedures for quality units are not in writing and/or followed to ensure the API and intermediates manufactured...
Aarti Drugs Limited
20 Sep 2024 Normal Justification: The observation of repeat training requirements for similar issues demonstrates a flaw in the training management system.
Excerpt: Activities at the facility are inadequately completed despite training given. Several personnel retrained on the same topic...
View Details
Written procedures are not followed that describe the in-process controls to be conducted on appropriate samples of in-process materials of each batch.
Granules India Limited
06 Sep 2024 Normal Justification: Improper execution of procedures indicates deficiencies in training management and understanding of SOPs.
Excerpt: Your operator verbally confirmed that they did not count the tablets nor did they look at both sides.
View Details
Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination
Zydus Lifesciences Limited
29 Aug 2024 Normal Justification: Effective training is fundamental to ensuring that operators adhere to critical aseptic protocols, preventing contamination.
Excerpt: operators touched (b)(4) stoppers with the (b)(4) restricted access barrier system
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.